000842640 001__ 842640
000842640 005__ 20210129232415.0
000842640 0247_ $$2Handle$$a2128/16847
000842640 037__ $$aFZJ-2018-00847
000842640 041__ $$aEnglish
000842640 1001_ $$0P:(DE-HGF)0$$aBrzozowska, Kinga$$b0$$eCorresponding author
000842640 1112_ $$a13. Jahrestagung der Gesellschaft für Biologische Strahlenforschung$$cHamburg$$d2010-09-01 - 2010-09-02$$gGBS$$wGermany
000842640 245__ $$aComparison of individual radiosensitivity of peripheral blood lymphocytes from prostate cancer patients and healthy donors
000842640 260__ $$c2010
000842640 3367_ $$033$$2EndNote$$aConference Paper
000842640 3367_ $$2BibTeX$$aINPROCEEDINGS
000842640 3367_ $$2DRIVER$$aconferenceObject
000842640 3367_ $$2ORCID$$aCONFERENCE_POSTER
000842640 3367_ $$2DataCite$$aOutput Types/Conference Poster
000842640 3367_ $$0PUB:(DE-HGF)24$$2PUB:(DE-HGF)$$aPoster$$bposter$$mposter$$s1517207408_23350$$xAfter Call
000842640 520__ $$aIntroduction: There is some evidence that approximately 10% of the population show an enhanced intrinsic radiosensitivity of normal tissue and hence have a higher risk for developing side-effects during or after radiotherapy. For that reason there is a need for a fast and robust test to assess normal tissue response to radiotherapy. DNA repair deficiency and altered apoptosis characteristics are discussed as promising markers of radiosensitivity. The aim of our study was to find out whether peripheral blood lymphocytes from cancer patients with strong clinical side effects following radiotherapy as assessed clinically on the basis of the EPIC questionnaire, show enhanced rates of in vitro radiation-induced double strand breaks (dsb), decreased DNA repair capacity and altered induction of apoptosis when compared to lymphocytes from patients without side effects and healthy age–matched donors. Materials and methods: The study included 20 prostate cancer patients without and 20 patients with acute side-effects during and after radiothrapy, as well as 20 healthy age-matched donors. From each donor, blood samples were collected, exposed to a radiation dose of 0.5 Gy or 1 Gy of  γ –rays and analysed for the following biological endpoints: the initial level of dsb and the repair kinetics (γ–H2AX–assay), apoptosis (Annexin V/PI–assay) and the induction of chromatid–type chromosomal aberrations (G2–assay). Results:  Significant higher chromatid aberration yield was found between prostate cancer patients and healthy donors. Eleven patients which suffered because of acute side-effects after radiotherapy showed an enhanced aberration level. In addition, an elevated aberration level was observed also in 11 patients without side-effects after radiotherapy. No differences were observed between both patients group in any in vitro assay. Based on the results of all chosen assays 6 prostate cancer patients were identified as cellular sensitive, whereof 4 of them were also clinical sensitive.
000842640 536__ $$0G:(DE-HGF)POF3-899$$a899 - ohne Topic (POF3-899)$$cPOF3-899$$fPOF III$$x0
000842640 65027 $$0V:(DE-MLZ)SciArea-160$$2V:(DE-HGF)$$aBiology$$x0
000842640 7001_ $$0P:(DE-HGF)0$$aPinkawa, Michael$$b1
000842640 7001_ $$0P:(DE-HGF)0$$aEble, Michael$$b2
000842640 7001_ $$0P:(DE-HGF)0$$aMüller, Wolfgang-Ulrich$$b3
000842640 7001_ $$0P:(DE-HGF)0$$aWojcik, Andrzej$$b4
000842640 7001_ $$0P:(DE-Juel1)133469$$aKriehuber, Ralf$$b5$$ufzj
000842640 7001_ $$0P:(DE-Juel1)133346$$aSchmitz, Sabine$$b6$$ufzj
000842640 8564_ $$uhttps://juser.fz-juelich.de/record/842640/files/Brzozowska%20et%20al%20GBS%202010%20Hamburg.pdf$$yOpenAccess
000842640 8564_ $$uhttps://juser.fz-juelich.de/record/842640/files/Brzozowska%20et%20al%20GBS%202010%20Hamburg.gif?subformat=icon$$xicon$$yOpenAccess
000842640 8564_ $$uhttps://juser.fz-juelich.de/record/842640/files/Brzozowska%20et%20al%20GBS%202010%20Hamburg.jpg?subformat=icon-1440$$xicon-1440$$yOpenAccess
000842640 8564_ $$uhttps://juser.fz-juelich.de/record/842640/files/Brzozowska%20et%20al%20GBS%202010%20Hamburg.jpg?subformat=icon-180$$xicon-180$$yOpenAccess
000842640 8564_ $$uhttps://juser.fz-juelich.de/record/842640/files/Brzozowska%20et%20al%20GBS%202010%20Hamburg.jpg?subformat=icon-640$$xicon-640$$yOpenAccess
000842640 8564_ $$uhttps://juser.fz-juelich.de/record/842640/files/Brzozowska%20et%20al%20GBS%202010%20Hamburg.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000842640 909CO $$ooai:juser.fz-juelich.de:842640$$pdriver$$pVDB$$popen_access$$popenaire
000842640 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-HGF)0$$aForschungszentrum Jülich$$b0$$kFZJ
000842640 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a S-US$$b0
000842640 9101_ $$0I:(DE-588b)36225-6$$6P:(DE-HGF)0$$aRWTH Aachen$$b1$$kRWTH
000842640 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Universitätsklinik für Strahlentherapie$$b1
000842640 9101_ $$0I:(DE-588b)36225-6$$6P:(DE-HGF)0$$aRWTH Aachen$$b2$$kRWTH
000842640 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Universitätsklinik für Strahlentherapie$$b2
000842640 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Universität Duisburg-Essen$$b3
000842640 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Institut für Med. Strahlenbiologie$$b3
000842640 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$aExternal Institute$$b4$$kExtern
000842640 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)133469$$aForschungszentrum Jülich$$b5$$kFZJ
000842640 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)133346$$aForschungszentrum Jülich$$b6$$kFZJ
000842640 9131_ $$0G:(DE-HGF)POF3-899$$1G:(DE-HGF)POF3-890$$2G:(DE-HGF)POF3-800$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000842640 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000842640 920__ $$lyes
000842640 9201_ $$0I:(DE-Juel1)S-US-20090406$$kS-US$$lSicherheit und Strahlenschutz, Umgebungsüberwachung,Strahlenbiologie$$x0
000842640 980__ $$aposter
000842640 980__ $$aVDB
000842640 980__ $$aUNRESTRICTED
000842640 980__ $$aI:(DE-Juel1)S-US-20090406
000842640 9801_ $$aFullTexts